Arpesh Mehta is an Investment Director with dsm-firmenich Ventures where, in addition to Miach, he manages investments in CollaMedix, Interface Biologics, Ripple Therapeutics, among others. Prior to dsm-firmenich, Arpesh worked within the private equity division of Black River Asset Management and held various R&D and commercial roles within the biotech industry. Arpesh holds a bachelor’s degree in biology from the University of Pennsylvania, master’s degree in biomedical engineering from UCLA, and masters of business administration from Northwestern University.